SG11201901059QA - Methods for purifying antibodies - Google Patents

Methods for purifying antibodies

Info

Publication number
SG11201901059QA
SG11201901059QA SG11201901059QA SG11201901059QA SG11201901059QA SG 11201901059Q A SG11201901059Q A SG 11201901059QA SG 11201901059Q A SG11201901059Q A SG 11201901059QA SG 11201901059Q A SG11201901059Q A SG 11201901059QA SG 11201901059Q A SG11201901059Q A SG 11201901059QA
Authority
SG
Singapore
Prior art keywords
international
prussia
king
road
rule
Prior art date
Application number
SG11201901059QA
Other languages
English (en)
Inventor
Andre C Dumetz
Kent E Goklen
Nicholas E Levy
Jessica Rachel Molek
Andrew S Thomson
Kenneth G Yancey
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of SG11201901059QA publication Critical patent/SG11201901059QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11201901059QA 2016-09-07 2017-09-06 Methods for purifying antibodies SG11201901059QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662384240P 2016-09-07 2016-09-07
PCT/IB2017/055374 WO2018047080A1 (en) 2016-09-07 2017-09-06 Methods for purifying antibodies

Publications (1)

Publication Number Publication Date
SG11201901059QA true SG11201901059QA (en) 2019-03-28

Family

ID=60138654

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901059QA SG11201901059QA (en) 2016-09-07 2017-09-06 Methods for purifying antibodies

Country Status (12)

Country Link
US (2) US11530238B2 (ru)
EP (1) EP3510042B1 (ru)
JP (3) JP7058272B2 (ru)
KR (1) KR102489451B1 (ru)
CN (1) CN109689675A (ru)
AU (1) AU2017323583A1 (ru)
BR (1) BR112019004459A2 (ru)
CA (1) CA3035853A1 (ru)
IL (1) IL265016B (ru)
RU (1) RU2759909C2 (ru)
SG (1) SG11201901059QA (ru)
WO (1) WO2018047080A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202000891A (zh) * 2018-03-07 2020-01-01 英商葛蘭素史克智慧財產發展有限公司 純化抗體之方法
TW202003555A (zh) * 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
WO2019213527A1 (en) * 2018-05-04 2019-11-07 Sigma-Aldrich Co. Llc Engineered cells with modified host cell protein profiles
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
US20230143163A1 (en) * 2020-04-27 2023-05-11 Alexion Pharmaceuticals, Inc. Protein a chromatography purification of an antibody
CN113281430A (zh) * 2021-05-11 2021-08-20 苏州君盟生物医药科技有限公司 一种双特异性抗体的分离鉴定方法
CN115161308A (zh) * 2022-06-13 2022-10-11 江苏丰华生物制药有限公司 一种注射用替奈普酶上清液的纯化方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
EP2272378B1 (en) 2001-06-01 2014-08-06 Upfront Chromatography A/S Fractionation of protein containing mixtures
EP2277913A3 (en) 2001-08-10 2012-08-08 Aberdeen University Antigen binding domains from fish
CN100403028C (zh) 2002-05-31 2008-07-16 印度农业研究委员会 Bt-cry毒素的迅速检测
WO2005082937A2 (en) 2004-02-27 2005-09-09 Octapharma Ag A method of providing a purified, virus safe antibody preparation
WO2005113604A2 (en) 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
ES2662042T3 (es) 2006-01-06 2018-04-05 Emd Millipore Corporation Matrices cromatográficas de afinidad y métodos de fabricación y utilización de las mismas
US8263750B2 (en) 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
EP2004689A4 (en) * 2006-04-05 2010-06-02 Abbott Biotech Ltd PURIFICATION OF ANTIBODIES
CL2007002615A1 (es) * 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
WO2008085988A1 (en) 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
SI2848625T1 (sl) * 2008-08-14 2019-11-29 Genentech Inc Postopki za odstranjevanje kontaminanta z uporabo ionskoizmenjevalne membranske kromatografije z izpodrinjenjem nativnega proteina
CN107915769A (zh) 2011-03-29 2018-04-17 葛兰素史密斯克莱有限责任公司 用于蛋白纯化的缓冲液体系
WO2014141150A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Methods for purifying antibodies
JP2016519145A (ja) * 2013-05-15 2016-06-30 メディミューン リミテッド 組換え産生ポリペプチドの精製
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
SG11201601823TA (en) * 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides

Also Published As

Publication number Publication date
US20230046182A1 (en) 2023-02-16
AU2017323583A1 (en) 2019-03-14
KR20190043601A (ko) 2019-04-26
US20210284686A1 (en) 2021-09-16
RU2019109975A (ru) 2020-10-08
US11530238B2 (en) 2022-12-20
KR102489451B1 (ko) 2023-01-16
CN109689675A (zh) 2019-04-26
IL265016B (en) 2021-10-31
RU2019109975A3 (ru) 2020-12-17
EP3510042B1 (en) 2024-05-22
CA3035853A1 (en) 2018-03-15
WO2018047080A1 (en) 2018-03-15
JP2019530744A (ja) 2019-10-24
BR112019004459A2 (pt) 2019-05-28
JP2022058441A (ja) 2022-04-12
JP2024037787A (ja) 2024-03-19
JP7058272B2 (ja) 2022-04-21
EP3510042A1 (en) 2019-07-17
RU2759909C2 (ru) 2021-11-18

Similar Documents

Publication Publication Date Title
SG11201901059QA (en) Methods for purifying antibodies
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11202000105QA (en) Anti-cd166 antibodies and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201907531XA (en) Constraining motion vector information derived by decoder-side motion vector derivation
SG11201903835WA (en) Antibodies directed against programmed death- 1 (pd-1)
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201909011PA (en) Niraparib compositions
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201900844UA (en) Amino pyrimidine ssao inhibitors
SG11201901066UA (en) Novel alkaline stable immunoglobulin-binding proteins
SG11201900201YA (en) Methods for quantitating individual antibodies from a mixture
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201811015RA (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201809331RA (en) Antibodies recognizing tau
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof